All work is non-clinical and mechanistic in nature
Batch Purity Report Janoshik Verified Current Batch: Pending first shipment Every batch of GHK-Cu sold by Pepspan is independently tested by Janoshik Analytical (Prague, Czech Republic)
Among prediabetic participants, 87.7% reverted to normoglycemia with the combination, compared with 32.2% on placebo
BPC-157 works primarily through three major signaling pathways: VEGF (Vascular Endothelial Growth Factor) activation: BPC-157 powerfully stimulates VEGF, the primary driver of angiogenesis the formation of new blood vessels
It is recommended to frequently monitor blood levels of potassium and platelet counts in these individuals for early detection and appropriate management of any abnormalities
Separately, FDA lists GHK-Cu for injectable routes under safety concerns, citing immunogenicity risk and limited human safety data [8]